Topical Timolol Benefit in Venous Ulcers (EETUV)

NCT02422017 Phase 2 COMPLETED

Background: Venous Leg ulcers are a frequent pathology in dermatology and complex in their management. At the origin of high health costs and strong repercussions on quality of life for patients, they require long management and may be subject to possible complications. In spite of appropriate treatment, 50-60% of these ulcers are not healed at 24 weeks. Purpose: Topical beta adrenergic antagonists have shown efficacy in wound healing. The purpose of this study is to evaluate the efficacy and safety of treatment of chronic venous ulcers with topical timolol.

Details

Lead sponsor	Centre Hospitalier Universitaire, Amiens
Phase	Phase 2
Status	COMPLETED
Enrolment	42
Start date	2015-04
Completion	2018-01

Conditions

• Venous Leg Ulcers

Interventions

• Timolol
• Local care treatment

Primary outcomes

• Success rate — 12 weeks
  Assess the healing rate in patients treated with topical timolol associated with wound dressing and compression for 12 weeks, compared to patients treated with wound dressing and compression. Success is defined as an ulcer surface relative reduction \>= 40%

Countries

France